EGFR抑制剂对人结肠癌细胞株HT29中CD44+细胞及侧群细胞作用的研究

目的探讨表皮生长因子受体（EGFR）抑制剂对人结肠癌细胞株HT29中CD44+细胞及侧群（SP）细胞的作用机制。方法应用Hoechst33342染色、流式细胞仪检测HT29中CD44+细胞以及SP细胞比例和成瘤性，并对不同浓度EGFR抑制剂吉非替尼作用后球囊形成及SP细胞比例、不同化疗药物处理后CD44+细胞比例进行分析与比较。结果空白对照组HT29中SP细胞比例为（3.82±0.08）%，经维拉帕米阻断后降为（0.34±0.03）%，吉非替尼10、15滋mol/L作用48h后HT29中SP细胞比例明显降低（均P＜0.01），5-氟尿嘧啶（5-FU）作用48h后SP细胞比例变化不大（P＞0.05）。与空白对照组比较，吉非替尼7.5、10、15滋mol/L作用24、48h后CD44+细胞比例均明显降低（均P＜0.05）；且随着吉非替尼的浓度增大，CD44+细胞比例逐渐降低（P＜0.05）。与空白对照组比较，多烯紫杉醇、顺铂作用24、48h后CD44+比例均明显增大（均P＜0.05）。随着时间延长，加入不同浓度的吉非替尼对球囊形成均具有抑制作用。结论EGFR抑制剂对人结肠癌细胞株HT29中CD44+细胞及SP细胞具有生长抑制作用，且可抑制球囊形成。

Effect of epidermal growth factor receptor inhibitor on CD44+ cells and side population cells of human colon cancer cell line HT29

Objective To explore the effect of epidermal growth factor receptor (EGFR) inhibitor on CD44+ and side population (SP) cells in colon cancer HT-29 cells. Methods The proportion and tumorigenicity of CD44+ cells and SP cells was detected by Hoechst33342 staining and flow cytometry. The effects of EGFR inhibitor gefitinib at different concentrations on the sphere formation and the proportion of CD44+ cells and SP cells were analyzed. Results EGFR inhibitor significantly inhibited the growth of CD44+ cells and SP cells. The proportion of CD44+ cells in HT29 cells was decreased after treatment with gefitinib for24h and 48h. The proportion of SP cells in HT29 cells was decreased from (3.82 ±0.08)% to (0.34 ±0.03)% after verapamiltreatment. It was also decreased significantly after gefitinib treatment. Gefitinib had an inhibitory effect on the sphere formation in HT29 cells. Conclusion There are CD44+ and SP cells subpopulation in colon cancer cells. EGFR inhibitor can inhibit the growth of CD44+ and SP cells in colon cancer HT-29 cells, which may provide information for targeting therapy of colon cancer.